Search Results for 'pfs'

pfs published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)

Median PFS: 2.6 months (95% CI, 1.7-3.5)

by ceila

Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...

Partnerships for Success

Partnerships for Success

by test

Creating Positive School Experiences And Develop...

Beyond Secret Handshakes:

Beyond Secret Handshakes:

by pasty-toler

Affiliation-Hiding Authenticated Key Exchange. Fr...

2014 Oklahoma Business Summit

2014 Oklahoma Business Summit

by marina-yarberry

Sarah Roberts, Inasmuch Foundation, Program Offic...

Thierry Le Chevalier, MD

Thierry Le Chevalier, MD

by yoshiko-marsland

How . d. o International Regulatory Groups View C...

by danika-pritchard

Director of Solutions Architecture and Field Enab...

Blinded Sample Size Re-estimation in a Phase III Study Inve

Blinded Sample Size Re-estimation in a Phase III Study Inve

by luanne-stotts

David Morgan (King’s College, London / Consulta...

Thierry Le Chevalier, MD

Thierry Le Chevalier, MD

by aaron

How . d. o . International Regulatory Groups View...

Applying “Pay for Success” Social Impact Finance to Ear

Applying “Pay for Success” Social Impact Finance to Ear

by luanne-stotts

Janis Dubno, Voices for Utah Children. Andrea Phi...

Her-2 negative MBC

Her-2 negative MBC

by conchita-marotz

10/25/2016. Objectives. General principles. Endoc...

Interpretation of the Great Plains Polygonal Fault

Interpretation of the Great Plains Polygonal Fault

by luanne-stotts

Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...

Btk inhibition in Mantle cell Lymphoma & CLL

Btk inhibition in Mantle cell Lymphoma & CLL

by test

Simon Rule. Professor of Clinical . Haematology. ...

BELLE-3: A Phase III Study of

BELLE-3: A Phase III Study of

by faustina-dinatale

Buparlisib. and . Fulvestrant. in Postmenopausa...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

by debby-jeon

Carcinoma: Balancing . Efficacy with Quality of L...

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

by olivia-moreira

Jointly provided by ...

End-points utilized in

End-points utilized in

by marina-yarberry

End-points utilized in breast cancer clinical ...

Game Plan Trends in ovarian cancer

Game Plan Trends in ovarian cancer

by alexa-scheidler

Diagnostic work-up. Treatment. The most commonly ...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

by vizettan

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

by wang

pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...

2022 Spring Oncology Conference

2022 Spring Oncology Conference

by byrne

Evolving Treatment Strategies. for CLL/SLL and MCL...

Update on Diagnosis and Treatments

Update on Diagnosis and Treatments

by joanne

of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...

ESMO 2021 (Virtual) Congress Report

ESMO 2021 (Virtual) Congress Report

by SnuggleBug

Lung and gastrointestinal cancers. Slide numbers. ...

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

by TravelingSoulmate

PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

by naomi

David Morgan (King’s College, London / Consultan...

Summary 2011 Founded 2010

Summary 2011 Founded 2010

by eliza

in Houston. Vision: To be the leader in the develo...

YIR On Demand Lung Benjamin Levy, MD

YIR On Demand Lung Benjamin Levy, MD

by jovita

Assistant Professor. Johns Hopkins School of Medic...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m

by felicity

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...

End-points utilized in breast cancer

End-points utilized in breast cancer

by evelyn

clinical . trials - Discussion. Novartis Oncology...

Pay for Success: Innovative Financing to Improve Child Outcomes

Pay for Success: Innovative Financing to Improve Child Outcomes

by dominic513

Jennifer Tschantz; Early Childhood Research to Pra...

Company proﬁ leProject name: Songwe Hill Rare Earths ProjectP

Company proﬁ leProject name: Songwe Hill Rare Earths ProjectP

by min-jolicoeur

PFS well advanced, favourable topography, simple w...

Multiple Myeloma – Is It Now Curable?

Multiple Myeloma – Is It Now Curable?

by celsa-spraggs

Andrzej . J. . Jakubowiak, MD, PhD. Director, Mye...

by phoebe-click

. Highlights from the Annual Clinical Meeting. G...

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t

by sherrill-nordquist

Yes . Deborah . Schrag. , MD, MPH. No. John L. Ma...

17th Annual International Congress

17th Annual International Congress

by conchita-marotz

on . Hematologic Malignancies. ®. : . Focus . on...

by ellena-manuel

Rajesh. Components of Database Engine. Issue Quer...

Calculating the Contribution to the Meal Pattern:

Calculating the Contribution to the Meal Pattern:

by pamella-moone

Product Formulation Statements. Webinar March 27,...

by tatiana-dople

Agents . for . Indolent . L. ymphoma . and . Mant...

Impact of Imatinib interruption & duration of prior Hyd

Impact of Imatinib interruption & duration of prior Hyd

by pamella-moone

Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...

by natalia-silvester

Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...